Ocrelizumab slows disability progression in advanced multiple sclerosis
Ocrelizumab slows disability even in advanced stages of multiple sclerosis. Is Briumvi a better option? A look at the data and costs.
English · Original discussion in Spanish · Published
Ocrelizumab shows efficacy in advanced stages of multiple sclerosis
A new clinical analysis, reported by Infosalus, suggests that ocrelizumab (Ocrevus) can slow disability pogre even in patients with advanced-stage multiple sclerosis. The finding reopens the debate over which biological treatment offers the best risk-benefit profile in this neurodegenerative disease.
Is Briumvi a superior alternative?
In the data analysis, a comparison with Briumvi (ublituximab), from TG Therapeutics, comes to the fore. Its advocates point out that it has a smaller "crap gap" —the window of symptom rebound between infusions— and, according to trials, does not raise the risk of breast cancer, an adverse effect that has hovered over ocrelizumab. The discussion includes a conflict-of-interest disclosure: one of the participants admits to holding shares in TG Therapeutics, introducing a well-known bias into the comparison.
The cost of the alternatives
Meanwhile, Sativex is mentioned, a THC-based drug approved in the UK for spasticity, priced at £500 per small pack. Its effectiveness, although proven, runs into an economic barrier that puts it out of reach for many patients.
The final message is one of skepticism: while the industry competes for the best label, patients are still waiting for answers about which brand actually slows the disease without hidden side effects.
Related debates in the forum
A new clinical analysis, reported by Infosalus, suggests that ocrelizumab (Ocrevus) can slow disability pogre even in patients with advanced-stage multiple sclerosis. The finding reopens the debate over which biological treatment offers the best risk-benefit profile in this neurodegenerative disease.
Is Briumvi a superior alternative?
In the data analysis, a comparison with Briumvi (ublituximab), from TG Therapeutics, comes to the fore. Its advocates point out that it has a smaller "crap gap" —the window of symptom rebound between infusions— and, according to trials, does not raise the risk of breast cancer, an adverse effect that has hovered over ocrelizumab. The discussion includes a conflict-of-interest disclosure: one of the participants admits to holding shares in TG Therapeutics, introducing a well-known bias into the comparison.
The cost of the alternatives
Meanwhile, Sativex is mentioned, a THC-based drug approved in the UK for spasticity, priced at £500 per small pack. Its effectiveness, although proven, runs into an economic barrier that puts it out of reach for many patients.
The final message is one of skepticism: while the industry competes for the best label, patients are still waiting for answers about which brand actually slows the disease without hidden side effects.
Related debates in the forum
Also available in: Deutsch
Summary of a discussion on Burbuja.info - Foro de economía, actualidad y política., translated from Spanish and reviewed before publication. Read the full discussion (16 replies).
More summaries
-
How hard is it to get Derek Vinyard's physique without gym money?
Is it possible to achieve Derek Vinyard's physique without a gym or chemicals? We analyze the feasibility of this goal with calisthenics and natural training.
-
Restora de Montó and other paints: which brands are worth it
Pinturas Montó's Restora Professional Premium costs 14 euros for a 4-litre can and no one confirms its quality, compared to Juno, Bruguer or Valentine.
-
Replacing xenon bulbs: what DIY drivers need to know
Thinking of replacing your xenon bulbs yourself? Learn about the electrical risks, key safety tips and how to save money on your car's lighting maintenance.
-
Marathon and cardio experts torn over home training debate
A heated debate over home cardio, calisthenics and the difference between real training and just easing your conscience. What is enough?
-
Arcades become a refuge for men fleeing life at home
Men hiding out in gaming arcades to escape their homes. We look at the phenomenon of loneliness and the search for public spaces in the forum.
-
Testing my urine pH at home with test strips
We look at the growing trend of measuring urinary pH at home with test strips. Is it a useful health tool or an obsession with no scientific basis?